ArticleFrontiers in genetics2026
Cord blood-based neonatal genetic screening for thalassemia in Guiyang, China (2015): a cross-sectional study.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to assess the carrier frequency and molecular spectrum of thalassemia in neonates from Guiyang, China, a multi-ethnic region with historically limited population-level screening data. Methods: This single-center cross-sectional study recruited 1,000 consecutive umbilical cord blood samples from full-term neonates delivered at a tertiary maternal and child health hospital in Guiyang from January 2015 to December 2015. Genetic screening for thalassemia was conducted using commercial gene detection kits. Epidemiological data, including sex, age, ethnicity, place of origin, and routine blood test results, were obtained from the parents of all subjects. High-throughput sequencing was employed to re-examine cord blood samples from neonates whose parents had reduced MCV or a family history of thalassemia. Results: Of the 1,000 neonates, 74 were identified as thalassemia carriers, yielding an overall carrier rate of 7.4%. Specifically, 55 cases (5.5%) carried α-thalassemia genes, 18 cases (1.8%) carried β-thalassemia genes, and 1 case (0.1%) was a compound αβ-thalassemia carrier. Among α-thalassemia carriers, the three most frequent deletion genotypes were -α Conclusion: This neonatal cord blood screening study in Guiyang reveals an overall thalassemia carrier rate of 7.4%, with α-thalassemia predominating. The -α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.